Roche said it will stop development of emugrobart, an experimental treatment for spinal muscular atrophy (SMA), after a key study failed to show consistent improvements in muscle growth and motor function. The company informed European patients directly in a letter outlining the decision. Roche attributed the program termination to insufficient efficacy signals in an important trial. The move removes a candidate from a crowded SMA landscape and shifts development focus back to other programs within Roche’s neuromuscular portfolio.